World news – GB – Coronavirus: Brazil stops trial of Sinovac vaccine after the death of an ‘unconnected’ volunteer

0

The medical research institute running the trial says it was « surprised » by this move, adding that the volunteer’s death was not related

The Brazilian health regulator has halted clinical trials of the Coronavirus vaccine manufactured by the Chinese pharmaceutical company Sinovac after a « serious adverse effect »

The regulator, Anvisa, did not provide any further details but said the accident occurred on October 29

“With the suspension of studies, it is not possible to vaccinate any new volunteers,” according to a statement on his website.

The head of the Bhutantan Institute for Medical Research in São Paulo, which is running COVID-19 vaccine trials in Brazil, told local television that one of the volunteers died – but not from a jab

Dimas Covas said the decision to stop the trials was linked to death, but said he was « surprised » that the death was « unrelated to the vaccine »

« Since there are more than 10,000 volunteers at this moment, there could be deaths. It is a death unrelated to the vaccine and as such, it is not the time to cut the trials. »

The state government of São Paulo also expressed surprise at the decision, saying in a statement that it “regrets being reported by the press and not directly by Anvisa, as is often the case in clinical trials of this kind”

The Instituto Butantan will predominantly produce the CoronaVac vaccine in Brazil that is being tested in seven states and the Federal District, including the capital, Brasilia

The trial has already sparked controversy in Brazil, with President Jair Bolsonaro questioning its potential effectiveness

The announcement came after news that his Health Minister, Eduardo Pazuelo, agreed to buy locally produced CoronaVac doses of Butantan.

Despite the confusion caused by the government, Anvisa gave the green light to import six million doses from China

On Monday, São Paulo Health Minister Jan Gornstein said that the first 120,000 rounds of Corona will arrive at the state airport on November 20.

Raw materials to produce another 40 million rounds will start arriving a week later.

“We will continue to follow health protocols for giving the shots. They will only be passed on to the public after obtaining final permission from the Brazilian health regulator,” said Mr. Gornstein.

He added that nearly all of the volunteers who were given two doses of the vaccine had produced antibodies believed to protect people from the virus.

As of July, thousands of employees of Chinese state-owned companies have already received the vaccine before traveling abroad

Then a new campaign expanded this offer to the general public, in a few cities and towns, with some restrictions in place requiring volunteers between the ages of 18 and 59, and a local resident

Pausing drug and vaccine tests is a relatively common step that allows researchers to verify whether or not a disease is a side effect

Last month, two drugmakers resumed testing potential coronavirus vaccines in the United States after they were discontinued

On Monday, it was announced that a product developed by Pfizer and BioNTech is 90% effective in preventing infection

British Health Secretary Matt Hancock told Sky News that the NHS has been asked to be ready to roll out this vaccine in early December.

© 2020 Sky UK

Vaccine, Sinovac Biotech, Brazil, Joao Doria, Botantan Institute

World News – GB – Coronavirus: Brazil discontinued Sinovac vaccine trial after the death of an « unrelated » volunteer
Related title :
– <a href="/?s=Coronavirus: The Oxford vaccine trial in Brazil will continue after the volunteer who took the placebo 13 "died" Coronavirus : The Oxford vaccine trial will continue in Brazil after the death of the volunteer who took the placebo. Sao Paulo started building the Chinese Sinovac vaccine production plant &: Governor


SOURCE: https://www.w24news.com

Donnez votre avis et abonnez-vous pour plus d’infos

[gs-fb-comments]

[comment]

[supsystic-newsletter-form id=4]

Vidéo du jour: